{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:06:36Z","timestamp":1793743596566,"version":"4.6.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T00:00:00Z","timestamp":1625529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.breast.2021.07.004","type":"journal-article","created":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T02:32:01Z","timestamp":1625625121000},"page":"157-164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: A population-based cohort study"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0409-1651","authenticated-orcid":false,"given":"Maria","family":"Sund","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4811-2330","authenticated-orcid":false,"given":"Miguel","family":"Garcia-Argibay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Garmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6392-273X","authenticated-orcid":false,"given":"Johan","family":"Ahlgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Karin","family":"Wennstig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irma","family":"Fredriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Lindman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6059-0194","authenticated-orcid":false,"given":"Antonis","family":"Valachis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2021.07.004_bib1","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","article-title":"Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials","volume":"386","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2021.07.004_bib2","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s10549-017-4282-9","article-title":"Risk of death from cardiovascular disease following breast cancer: a systematic review","volume":"164","author":"Gernaat","year":"2017","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.breast.2021.07.004_bib3","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1210\/js.2019-00096","article-title":"Cardiometabolic effects of endocrine treatment of estrogen receptor-positive early breast cancer","volume":"3","author":"Cheung","year":"2019","journal-title":"J\u00a0Endocr Soc"},{"key":"10.1016\/j.breast.2021.07.004_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejca.2016.08.022","article-title":"The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer","volume":"68","author":"Abdel-Qadir","year":"2016","journal-title":"Eur J Canc"},{"key":"10.1016\/j.breast.2021.07.004_bib5","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1001\/jamaoncol.2016.0429","article-title":"Cardiovascular disease after aromatase inhibitor use","volume":"2","author":"Haque","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.breast.2021.07.004_bib6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/clc.23114","article-title":"Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population-based study","volume":"42","author":"Kamaraju","year":"2019","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.breast.2021.07.004_bib7","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1161\/CIRCULATIONAHA.119.044750","article-title":"Aromatase inhibitors and the risk of cardiovascular outcomes in women with breast cancer: a population-based cohort study","volume":"141","author":"Khosrow-Khavar","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.breast.2021.07.004_bib8","doi-asserted-by":"crossref","first-page":"k3845","DOI":"10.1136\/bmj.k3845","article-title":"Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review","volume":"363","author":"Matthews","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.breast.2021.07.004_bib9","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx141","article-title":"Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis","volume":"110","author":"Goldvaser","year":"2018","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.breast.2021.07.004_bib10","article-title":"Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials","author":"Qian","year":"2019","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.breast.2021.07.004_bib11","first-page":"e578","article-title":"Extended adjuvant therapy with aromatase inhibitors for early breast cancer: a meta-analysis of randomized controlled trials","volume":"19","author":"Xu","year":"2019","journal-title":"Clin Breast Canc"},{"key":"10.1016\/j.breast.2021.07.004_bib12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10549-020-05930-w","article-title":"Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study","volume":"185","author":"Jacobse","year":"2021","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.breast.2021.07.004_bib13","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s10549-011-1754-1","article-title":"Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients","volume":"131","author":"Ligibel","year":"2012","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.breast.2021.07.004_bib14","article-title":"Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors","author":"Matthews","year":"2020","journal-title":"Heart"},{"key":"10.1016\/j.breast.2021.07.004_bib15","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1186\/s12889-019-6846-6","article-title":"Validation of data quality in the Swedish national register for breast cancer","volume":"19","author":"L\u00f6fgren","year":"2019","journal-title":"BMC Publ Health"},{"key":"10.1016\/j.breast.2021.07.004_bib16","series-title":"National quality register for breast cancer (NKBC). The Swedish association of local authorities and regions (SALAR)","year":"2021"},{"key":"10.1016\/j.breast.2021.07.004_bib17","series-title":"The Swedish association of local authorities and regions (SALAR). National quality registry for breast cancer. The Swedish association of local authorities and regions (SALAR)","year":"2020"},{"key":"10.1016\/j.breast.2021.07.004_bib18","series-title":"The Swedish prescribed drug register","year":"2020"},{"key":"10.1016\/j.breast.2021.07.004_bib19","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/pds.1294","article-title":"The new Swedish Prescribed Drug Register--opportunities for pharmacoepidemiological research and experience from the first six months","volume":"16","author":"Wettermark","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.breast.2021.07.004_bib20","series-title":"Longitudinal integrated database for health insurance and labour market studies","year":"2020"},{"key":"10.1016\/j.breast.2021.07.004_bib21","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A\u00a0new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J\u00a0Chron Dis"},{"key":"10.1016\/j.breast.2021.07.004_bib22","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Publ Health"},{"key":"10.1016\/j.breast.2021.07.004_bib23","series-title":"National patient register","year":"2020"},{"key":"10.1016\/j.breast.2021.07.004_bib24","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s10654-017-0316-1","article-title":"The Swedish cause of death register","volume":"32","author":"Brooke","year":"2017","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.breast.2021.07.004_bib25","series-title":"R: a language and environment for statistical computing","year":"2020"},{"key":"10.1016\/j.breast.2021.07.004_bib26","first-page":"141","article-title":"Long-term cardiac and vascular disease outcomes following adjuvant tamoxifen therapy: current understanding of impact on physiology and overall survival","volume":"104","author":"Onitilo","year":"2013","journal-title":"Minerva Med"},{"key":"10.1016\/j.breast.2021.07.004_bib27","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000008723","article-title":"Effects of treatment with chemotherapy and\/or tamoxifen on the biomarkers of cardiac injury and oxidative stress in women with breast cancer","volume":"96","author":"Silva","year":"2017","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.breast.2021.07.004_bib28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13293-017-0152-8","article-title":"The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy","volume":"8","author":"Iorga","year":"2017","journal-title":"Biol Sex Differ"},{"key":"10.1016\/j.breast.2021.07.004_bib29","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1161\/CIRCULATIONAHA.117.029652","article-title":"Socioeconomic status and cardiovascular outcomes: challenges and interventions","volume":"137","author":"Schultz","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.breast.2021.07.004_bib30","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1161\/CIRCRESAHA.120.317062","article-title":"Tamoxifen accelerates endothelial healing by targeting ER\u03b1 in smooth muscle cells","volume":"127","author":"Zahreddine","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.breast.2021.07.004_bib31","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1212\/01.WNL.0000140491.54664.50","article-title":"Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis","volume":"63","author":"Bushnell","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.breast.2021.07.004_bib32","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials","volume":"378","author":"Davies","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2021.07.004_bib33","article-title":"Long-Term prognostication for 20\u2009114 women with small and node-negative breast cancer\u2002(T1abN0)","volume":"5","author":"Jaraj","year":"2020","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.breast.2021.07.004_bib34","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/eurjhf\/hft064","article-title":"The epidemiology of heart failure, based on data for 2.1 million inhabitants in Sweden","volume":"15","author":"Zarrinkoub","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.breast.2021.07.004_bib35","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S1470-2045(18)30116-5","article-title":"Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial","volume":"19","author":"De Placido","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2021.07.004_bib36","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S1470-2045(11)70270-4","article-title":"Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8\u00b71 years median follow-up","volume":"12","author":"Regan","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2021.07.004_bib37","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1200\/JCO.2015.64.3809","article-title":"American cancer society\/American society of clinical oncology breast cancer survivorship care guideline","volume":"34","author":"Runowicz","year":"2016","journal-title":"J\u00a0Clin Oncol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977621004124?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977621004124?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:44:23Z","timestamp":1760777063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977621004124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":37,"alternative-id":["S0960977621004124"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2021.07.004","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: A population-based cohort study","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2021.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}